Why did the researchers do this particular study?
To find out whether "multitarget" treatment with mycophenolate mofetil and tacrolimus could result in greater rates of complete remission in patients with newly diagnosed LN compared with standard treatment.
Who was studied?
A total of 368 patients who had a kidney biopsy that showed LN within the past 6 months, high levels of protein in their urine, and evidence of kidney disease and inflammation in their blood tests.
How was the study done?
Patients with LN were randomly assigned to the multitarget treatment or standard treatment. The patients in the multitarget group took mycophenolate mofetil and tacrolimus pills twice a day for 24 weeks and the patients in the standard treatment group received intravenous (IV) cyclophosphamide every 4 weeks for 6 doses. Both groups received IV steroids for 3 days, followed by oral steroids. The researchers evaluated the rates of complete remission in each group at 24 weeks. They also monitored the patients' blood work and clinical examinations to see whether any problems occurred. They recorded any side effects during the 6 months.
What did the researchers find?
The multitarget group had higher rates of complete remission and reached complete remission more quickly than the patients in the standard therapy group. The multitarget group also showed bigger improvements in laboratory measures of kidney function and inflammation. More patients in the multitarget group quit the study because of bad side effects, but the multitarget and standard treatment groups had a similar rate of side effects overall. No patients died in either treatment group.
What were the limitations of the study?
The study took place in China, so it is not clear whether patients from other countries would have the same rates of response to the multitarget therapy. In addition, because the study lasted only 24 weeks, long-term effects on the patients' kidney function are unknown.
What are the implications of the study?
Multitarget treatment of LN with mycophenolate mofetil and tacrolimus was better than standard treatment with cyclophosphamide. The side effects of the multitarget combination were similar to those seen with standard treatment. 
